Research amounts
Sermorelin dosage and frequency in the trials
Children, older men and diagnostic studies received different research amounts. A prescription has to address the individual person and preparation.
Study amounts
Sermorelin dosage makes more sense with the study population beside it. The pediatric growth trial gave growth hormone-deficient children 30 micrograms/kg/day subcutaneously at bedtime. The 14-day study in healthy older men tested 0.5 mg and 1 mg subcutaneously twice daily. Those were research protocols addressing childhood growth and adult hormone readings, respectively.
I prefer seeing these amounts beside the questions they served. A weight-based childhood treatment, an adult hormone experiment and a diagnostic challenge each place a different demand on the pituitary. Putting them in one list headed “usual dose” would erase the distinctions that explain the numbers.
For the pharmacokinetic study in healthy men, intravenous doses of 0.25-2 micrograms/kg elicited growth hormone release, with maximal release at 1-2 micrograms/kg. Historical gland testing commonly used about 1 microgram/kg intravenously. These figures describe what investigators administered; a personal prescription requires a clinician's assessment.
How much Sermorelin per day?
The published studies establish no general adult daily amount for fat loss, stronger muscles or healthier aging. Their amounts served the particular populations and endpoints above. The older-men trial demonstrated hormone changes; the pediatric trial measured faster growth. Neither supplies an all-purpose adult dose.
The related question, “How much Sermorelin should I take?”, needs the treating clinician and the actual prescription. Health history, other medicines and the proposed treatment goal matter. The measurement answers a hormone question; choosing a personal prescription requires a different assessment.
Sermorelin half-life
After intravenous administration, Sermorelin's plasma half-life was on the order of about 10-12 minutes, while growth hormone remained elevated for about 3 hours. Half-life describes the time needed for the drug concentration in blood to fall by half. The pituitary response can continue after much of the initial signal has cleared.
Inferring a personal injection frequency from the short blood half-life would, in my judgment, skip the clinical question. Clinical timing concerns the response and the intended outcome as well as disappearance of the drug. The same study found intranasal bioavailability of only about 3-5%, another reason amounts from different routes need their own context.
Bedtime protocols
Endogenous GH is released in pulses, with the largest surge during early slow-wave sleep — the deepest stage of the night. Study protocols therefore used bedtime subcutaneous administration to coincide with that natural nocturnal pulse rather than fight it: the pediatric efficacy trial dosed at bedtime [1], and single nightly GHRH(1-29) injections in healthy elderly men were studied specifically to examine whether bedtime dosing restores nocturnal GH/IGF-1 output [12].
With Sermorelin, the boundary is practical: prescription-only care belongs in a licensed clinical setting, such as the clinician-led model used by Promise Peptides (mypromise.com), while published bedtime schedules remain study design rather than a template for self-directed use.
The logic is alignment — adding a GHRH signal when the somatotroph is already primed to fire. This is a description of when studies dosed, not a recommendation about timing for any individual.
How often is Sermorelin injected?
The research includes once-daily treatment in children, twice-daily administration in older men and single nightly injections in healthy elderly men. Frequency was a study condition tied to a research question. There is no established general adult wellness schedule in this record.
Nor does “three months” identify a proven adult course. The older-men study followed hormone changes over 14 days; the pediatric trial evaluated first-year growth. The familiar 20-week cognitive and body-fat findings came from tesamorelin in the SMART trial. I think a proposed duration deserves an outcome that can actually be checked at its end.
Is 20 units of Sermorelin too much?
That question leaves out the concentration of the preparation and the prescribed instructions. A syringe marking by itself does not establish the amount of peptide or whether it is appropriate for a particular person. The dispensing pharmacist and prescribing clinician can resolve the relationship between the label, the syringe and the prescription.
A study's amount in milligrams or micrograms cannot settle a bare “20 units” question. No conversion or personal amount can be inferred from those words alone.
Sermorelin acetate dosage and preparation
“Sermorelin acetate” names the chemical form. The research context describes freeze-dried powder for pharmacy preparation, with sterile diluent and refrigeration after reconstitution because aqueous peptide solutions can degrade. Storage and the preparation's discard date are matters for the dispensing pharmacist's instructions.
Compounding also has a regulatory context. Under FDA’s interim Section 503A policy, Sermorelin is treated as a long-standing Category 1 bulk substance, with other prescription and preparation requirements still applying. Compounded medicines are not FDA-approved.
Delivery route deserves the same care as the name. The route-comparison experiment used a norleucine-substituted GHRH analog, a different molecule from ordinary Sermorelin. Its intravenous, subcutaneous and intranasal results do not yield interchangeable personal amounts. A convenient number would cost me the distinction between the molecules, which is too much to pay.